Vaccinating children aged under 5 years against covid-19

Saxena, Sonia; Wighton, Kate

doi:10.1136/bmj.o1863

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 22 Antigenic cartography studies have shown that omicron sublineages are separated from earlier SARS-CoV-2 variants with omicron BA.4 or BA.5 being the most distant. 11 …”

Section: Discussionmentioning

confidence: 99%

“…By contrast to the adult population, many children acquired COVID-19 immunity via natural infection rather than vaccination. 10 , 11 , 12 Understanding how much additional protection COVID-19 vaccination offers to current strains in previously infected people, and the potential option to strengthen population immunity resilience against emergent variants, will be crucial for public health.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study

Yung¹,

Pang²,

Kam³

et al. 2023

The Lancet Child & Adolescent Health

View full text Add to dashboard Cite

“… 22 Antigenic cartography studies have shown that omicron sublineages are separated from earlier SARS-CoV-2 variants with omicron BA.4 or BA.5 being the most distant. 11 …”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study

Yung¹,

Pang²,

Kam³

et al. 2023

The Lancet Child & Adolescent Health

View full text Add to dashboard Cite

“…Consequently, the U.S. Food and Drug Administration (FDA) recently authorized the emergency use of the Moderna and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include children down to 6 months of age (fda.gov by June 17, 2022). Despite the latest data about the safety and effectiveness of COVID-19 vaccines on mitigating future contraction rates, hospitalizations, long-term influence, and deaths in children [38,[39][40][41][42], worldwide officials raise controversies around immunization benefits and vaccine safety in such age groups, particularly children under five years. For many countries, including Vietnam, the vaccines have been approved only for children aged five and older, while few countries, such as the United States, Brazil, and Costa Rica, have vaccinated children from six months old [38].…”

Section: Discussionmentioning

confidence: 99%

High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-based Study

Tran¹,

Vu²,

Hoang³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: The robustness of sero-surveillence has delineated the high burden of SARS-CoV-2 infection in children; however, these existing data showed wide variation. This study aimed to identify the serostatus of antibodies against SARS-CoV-2 and associated factors among children following the fourth pandemic wave in Vietnam. Methods: A cross-sectional study was conducted at Vietnam National Children’s Hospital (VNCH) between March 13 and April 3, 2022. 4,032 eligible children seeking medical care for any medical condition not related to acute Covid-19 infections was tested for IgG SARS-CoV-2 Antibodies by ADVIA Centaur® SARS-CoV-2 IgG (sCOVG) assay using the residuals of routine blood samples. Results: The median age of enrolled children was 39 (IQR=14-82) months. The overall seropositive prevalence was 59.2%, and the median antibody titer was 4.78 [IQR 2.38-9.57] UI/mL. The risk of seropositivity and the median antibody titer was not related to gender (58.6% versus 60.1%, 4.9 versus 4.6 UI/mL, all p&gt;0.05). Among age groups, the highest seroprevalence was reported in the children aged 13 to &lt;36 months old. Children aged ≤12 months were likely to be seropositive compared to children aged 36 to &lt;60 months (59.2% versus 57.5%, p=0.49) and those aged ≥144 months (59.2% versus 65.5%, p=0.16). Children aged ≥144 months exhibited a significantly higher titer of protective COVID-19 antibodies than other age groups (p &lt;0.001). In multivariate logistic regression, we observed independent factors associated with SARS-CoV-2 seropositivity, including the age 13 to &lt;36 months (OR=1.29, 95%CI=1.06-1.56, p=0.01), 60 to &lt;144 months (OR=79, 95%CI=0.67-0.95, p=0.01), ≥144 months (OR=1.84, 95%CI=1.21-2.8, p=0.005), the presence of infected household members (OR=2.36, 95%CI=2.06–2.70, p&lt;0.001), participants from Hanoi (OR=1.54, 95%CI=1.34-1.77, p&lt;0.001), underlying conditions (OR=0.71, 95%CI=0.60-0.85, p&lt;=0.001), and using corticosteroids or immunosuppressants (OR=0.64, 95%CI=0.48-0.86, p=0.003). Conclusions: This study highlights a high seroprevalence of antibodies against SARS-CoV-2 among children seeking medical care for non-COVID-19-related conditions in a tertiary children’s hospital in Hanoi, Vietnam. In the context of reopening in-person schools and future emerged COVID-19 variants, this point will also be a key message about the necessity of “rush-out” immunization coverage for children, especially those under the age of three years.

show abstract

High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-Based Study

Tran

Hoang

et al. 2022

Pathogens

View full text Add to dashboard Cite

Background: The robustness of sero-surveillance has delineated the high burden of SARS-CoV-2 infection in children; however, these existing data showed wide variation. This study aimed to identify the serostatus of antibodies against SARS-CoV-2 and associated factors among children following the fourth pandemic wave in Vietnam. Methods: A cross-sectional study was conducted at Vietnam National Children’s Hospital (VNCH) between March 13 and April 3, 2022. Thus, 4032 eligible children seeking medical care for any medical condition not related to acute COVID-19 infection were tested for IgG SARS-CoV-2 antibodies by ADVIA Centaur® SARS-CoV-2 IgG (sCOVG) assay using the residuals of routine blood samples. Results: The median age of enrolled children was 39 (IQR = 14–82) months. The overall seropositive prevalence was 59.2% (95%CI = 57.6–60.7) and the median antibody titer was 4.78 (IQR 2.38–9.57) UI/mL. The risk of seropositivity and the median antibody titer were not related to gender (58.6% versus 60.1%, 4.9 versus 4.6 UI/mL, all p > 0.05). Children aged ≤12 months were likely to be seropositive compared to children aged 36 to <60 months (59.2% versus 57.5%, p = 0.49) and those aged ≥144 months (59.2% versus 65.5%, p = 0.16). Children aged ≥144 months exhibited a significantly higher titer of protective COVID-19 antibodies than other age groups (p < 0.001). In multivariate logistic regression, we observed independent factors associated with SARS-CoV-2 seropositivity, including the age 13 to <36 months (OR = 1.29, 95%CI = 1.06–1.56, p = 0.01), 60 to <144 months (OR = 0.79, 95%CI = 0.67–0.95, p = 0.01), ≥144 months (OR = 1.84, 95%CI = 1.21–2.8, p = 0.005), the presence of infected household members (OR = 2.36, 95%CI = 2.06–2.70, p < 0.001), participants from Hanoi (OR = 1.54, 95%CI = 1.34–1.77, p < 0.001), underlying conditions (OR = 0.71, 95%CI = 0.60–0.85, p ≤ 0.001), and using corticosteroids or immunosuppressants (OR = 0.64, 95%CI = 0.48–0.86, p = 0.003). Conclusions: This study highlights a high seroprevalence of antibodies against SARS-CoV-2 among children seeking medical care for non-acute COVID-19-related conditions in a tertiary children’s hospital in Hanoi, Vietnam. In the context of reopening in-person schools and future emerging COVID-19 variants, this point will also be a key message about the necessity of “rush-out” immunization coverage for children, especially those under the age of five years.

show abstract

Vaccinating children aged under 5 years against covid-19

Abstract: Whether other countries should follow the US’s lead is unclear

Cited by 3 publications

References 23 publications

BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study

BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study

High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-based Study

High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Children in Vietnam: An Observational, Hospital-Based Study

Contact Info

Product

Resources

About